The 36-month beta value for GPCR is also noteworthy at -3.48. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GPCR is 54.78M, and at present, short sellers hold a 19.06% of that float. The average trading volume of GPCR on November 14, 2024 was 664.23K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GPCR) stock’s latest price update
Structure Therapeutics Inc ADR (NASDAQ: GPCR)’s stock price has plunge by -0.23relation to previous closing price of 36.37. Nevertheless, the company has seen a -5.38% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-13 that Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity.
GPCR’s Market Performance
GPCR’s stock has fallen by -5.38% in the past week, with a monthly drop of -6.94% and a quarterly drop of -2.25%. The volatility ratio for the week is 4.62% while the volatility levels for the last 30 days are 5.92% for Structure Therapeutics Inc ADR The simple moving average for the last 20 days is -5.70% for GPCR stock, with a simple moving average of -9.53% for the last 200 days.
Analysts’ Opinion of GPCR
Many brokerage firms have already submitted their reports for GPCR stocks, with Morgan Stanley repeating the rating for GPCR by listing it as a “Overweight.” The predicted price for GPCR in the upcoming period, according to Morgan Stanley is $118 based on the research report published on September 23, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see GPCR reach a price target of $65. The rating they have provided for GPCR stocks is “Overweight” according to the report published on May 21st, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to GPCR, setting the target price at $65 in the report published on April 09th of the current year.
GPCR Trading at -7.93% from the 50-Day Moving Average
After a stumble in the market that brought GPCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.34% of loss for the given period.
Volatility was left at 5.92%, however, over the last 30 days, the volatility rate increased by 4.62%, as shares sank -6.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.23% lower at present.
During the last 5 trading sessions, GPCR fell by -3.18%, which changed the moving average for the period of 200-days by -14.88% in comparison to the 20-day moving average, which settled at $38.52. In addition, Structure Therapeutics Inc ADR saw -10.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GPCR
Current profitability levels for the company are sitting at:
- -107.05 for the present operating margin
- 0.12 for the gross margin
The net margin for Structure Therapeutics Inc ADR stands at -83.25. The total capital return value is set at -0.16. Equity return is now at value -17.71, with -17.09 for asset returns.
Based on Structure Therapeutics Inc ADR (GPCR), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -23.28. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -9.14.
Currently, EBITDA for the company is -102.46 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 1443.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 41.38.
Conclusion
In summary, Structure Therapeutics Inc ADR (GPCR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
